Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Vibsanin B Preferentially Targets HSP90β, Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis.
γδ T cells as early sensors of tissue damage and mediators of secondary neurodegeneration.
Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway.
The effect of group psycho-education program on the burden of family caregivers with multiple sclerosis patients in Isfahan in 2013-2014.
MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No.
Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS.
Social participation in patients with multiple sclerosis: correlations between disability and economic burden.
Neuro-Ophthalmic Syndromes and Processing Speed in Multiple Sclerosis.
[Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs].
[Therapeutic strategy for CIDP (chronic inflammatory demyelinating polyneuropathy)].
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis.
A common anesthesiology procedure for a patient with an uncommon combination of diseases: a case report.
Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis.
Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!
Statins and Neuroprotection: Basic Pharmacology Needed.
Current status of chemokines in the adult CNS.
Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs.
Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients.
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis.
Time to first relapse as an endpoint in multiple sclerosis clinical trials.
Sexual dysfunction in women with multiple sclerosis: Dimensions and contributory factors.
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study.
What is new in MS spasticity research? Poster session highlights.
S1P signaling: new therapies and opportunities.

Pages